BioPharmSignal logoBioPharmSignal

Biotech News

AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights

AN2 Therapeutics (ANTX)AN2 TherapeuticsEarnings

Cash, cash equivalents, and investments of $71.2 million at June 30,2025 and cash runway anticipated to fund operations into 2028 MENLO PARK, Calif. --(BUSINESS WIRE)--Aug. 12, 2025-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel

Open original release

Related news

ANTXAN2 Therapeutics2026-05-11 20:01 EST

AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights

ANTXAN2 Therapeutics2026-03-17 20:00 EST

AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights

ASMBAssembly Biosciences2026-05-07 20:00 EST

Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights

SPROSpero Therapeutics2025-08-05 16:05 EST

Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025

SPROSpero Therapeutics2026-05-05 16:05 EST

Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026

VIRIVirios Therapeutics2026-03-18 12:30 EST

Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

VIRIVirios Therapeutics2026-05-14 12:30 EST

Dogwood Therapeutics Announces First Quarter 2026 Financial Results

ASMBAssembly Biosciences2026-03-19 20:05 EST

Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights

BRNSBarinthus Biotherapeutics2025-08-07 12:00 EST

Barinthus Bio Reports Second Quarter 2025 Financial Results and Updates on Corporate Developments

ABUSArbutus2025-08-06 11:30 EST

Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update

View all latest news

AN2 Therapeutics

AN2 Therapeutics is an infectious-disease company focused on novel anti-infective medicines. Its platform is aimed at serious bacterial and related infectious conditions where new options matter.

Recent company news

ANTXAN2 Therapeutics2026-06-04 11:00 EST

AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease

ANTXAN2 Therapeutics2026-05-21 11:00 EST

AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

ANTXAN2 Therapeutics2026-05-11 20:01 EST

AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights

ANTXAN2 Therapeutics2026-05-07 20:01 EST

AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

ANTXAN2 Therapeutics2026-03-31 11:00 EST

AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease

Stock data

Close
4.70 USD
Market cap
146.59M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States